City
Epaper

Indian pharma sector will not suffer any loss due to Trump tariff: Former ICMR chief 

By IANS | Updated: August 12, 2025 20:10 IST

New Delhi, Aug 12 The Indian pharma sector, which supplies 80 per cent of the world's generic medicines, ...

Open in App

New Delhi, Aug 12 The Indian pharma sector, which supplies 80 per cent of the world's generic medicines, will not suffer any loss due to tariffs imposed by US President Donald Trump, the ICMR's former Director General, Dr N.K. Ganguly said.

The former Indian Council for Medical Research's (ICMR) remarks came amid concerns over the escalation of tariffs to 50 per cent on Indian goods by Trump.

"If any country in the world increases tariffs, it does not benefit them because the loss is suffered by that country only. India is a country that provides medicines at cheap rates and also exports them," Ganguly told IANS.

The noted microbiologist said that whether it is Europe or North America, the prices of drugs are very high in foreign countries.

And they do not make generic drugs because it requires manpower, a factory, etc., which are very expensive. In such a situation, generic drugs are imported from other countries.

"As a result, India will not suffer any loss due to this (US) tariff. The loss will be to those who have imposed this tariff because India is a country that provides medicines at the cheapest rates, and the maximum number of drugs are manufactured there," Ganguly told IANS.

India has also reduced the tariff on life-saving drugs, which are manufactured in India, so that the countries that need them can easily procure them.

Thus, "the country that has increased the tariff will suffer losses to its people because they will get medicines at higher rates", the former ICMR chief said.

While the initial duty of 25 per cent on export of Indian goods to the US came into effect from August 7, the additional levy will become effective from August 27.

Higher tariffs will make Indian goods, such as shrimps, organic chemicals, carpets, apparel (both knitted and woven), among others, costly in the US market.

Ganguly said that the prices of drugs are low in India as the country follows a pricing policy for drug manufacturing.

"Many schemes are also run by the government, due to which people get medicines at cheaper rates. Apart from this, medicines are also available at cheaper rates at the government-run pharmacy under the Pradhan Mantri Jan Aushadhi Yojana," the expert noted.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

NationalAdani Group chairman Gautam Adani and his wife offer prayers at Kedarnath temple on 40th wedding anniversary

Other SportsJSCA ropes in SJ Uplift to develop Jharkhand T20 Cricket League on seven-year mandate

BusinessPFCD Advocates for Insurance Coverage of Robotic Joint Replacement Surgery to Bridge India's Treatment Gap

BusinessWast Asia conflict may trigger USD 800 bn capex boost for India, but oil and fertiliser risks remain: Morgan Stanley

TechnologyGlobal crude prices rise 0.73 pc as US-Iran talks stall

Business Realted Stories

BusinessGlobal crude prices rise 0.73 pc as US-Iran talks stall

BusinessDeepak Chem Tech Limited enters into agreement to build HyCO plant to secure long-term supply of key raw material for its Polycarbonate Project

BusinessLabour Day: Gautam Adani launches ‘Apni Baat, Apno Ke Saath’ to connect with over 4 lakh colleagues

BusinessKora by NM Celebrates 15 Years of Crafting Modern Indian Occasionwear

BusinessOn the Founder's Day Manipal University Jaipur Launches New Industry-Oriented Academic Programs